Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Update

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) saw a large drop in short interest in October. As of October 15th, there was short interest totalling 26,400 shares, a drop of 22.8% from the September 30th total of 34,200 shares. Based on an average daily volume of 2,600,000 shares, the short-interest ratio is currently 0.0 days. Currently, 1.8% of the shares of the company are sold short.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on Galmed Pharmaceuticals in a research note on Wednesday, October 9th. They issued a “sell” rating for the company.

Galmed Pharmaceuticals Trading Down 6.2 %

GLMD opened at $3.66 on Wednesday. Galmed Pharmaceuticals has a 12-month low of $2.73 and a 12-month high of $23.80. The firm has a 50 day moving average of $4.82 and a two-hundred day moving average of $4.35. The firm has a market capitalization of $18.46 million, a PE ratio of -1.52 and a beta of 0.73.

Galmed Pharmaceuticals (NASDAQ:GLMD) last posted its quarterly earnings results on Wednesday, August 28th. The biopharmaceutical company reported $2.16 EPS for the quarter.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.